CANCER THERAPY TARGETING NKG2A

This invention relates to anti-NKG2A antibodies, optionally in combination with anti-PD-1 or anti-PD-L1 antibodies and/or anti-EGFR or anti-HER2 antibodies, and methods of using the antibodies or antibody combinations in enhancing immunity in a patient in need thereof and in treating cancer. La prés...

Full description

Saved in:
Bibliographic Details
Main Authors UHLENBROCK, FRANZISKA KATHARINA, ANDERSEN, DANIEL, NANCY-PORTEBOIS, VANESSA, LAUGEL, BRUNO, PIERRAT, MARIE-JEANNE, MELANDER, EVA MARIA CARLSEN, OCANA FERNANDEZ, ALBERTO
Format Patent
LanguageEnglish
French
Published 13.04.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:This invention relates to anti-NKG2A antibodies, optionally in combination with anti-PD-1 or anti-PD-L1 antibodies and/or anti-EGFR or anti-HER2 antibodies, and methods of using the antibodies or antibody combinations in enhancing immunity in a patient in need thereof and in treating cancer. La présente invention concerne des anticorps anti-NKG2A, éventuellement en combinaison avec des anticorps anti-PD-1 ou anti-PD-L1 et/ou des anticorps anti-EGFR ou anti-HER2, ainsi que des méthodes d'utilisation des anticorps ou des combinaisons d'anticorps pour renforcer l'immunité chez un patient le nécessitant et dans le traitement du cancer.
Bibliography:Application Number: CA20223233771